-
Mashup Score: 1JACC: CardioOncology: Vol 4, No 4 - 2 year(s) ago
MINI-FOCUS ISSUE: AMYLOIDOSIS AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review State-of-the-Art Review …
Source: www.jacc.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
Abstract Background Low QRS voltages (LQRSVs) are a common electrocardiographic feature in patients with light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis (CA). …
Source: JACC: CardioOncologyCategories: Cardiologists, Latest HeadlinesTweet-
So very, very sad. Dr. Rapezzi was a true giant in the field. We literally just e-published a manuscript of his 1 week ago in @JACCJournals #JACCCardioOnc. https://t.co/UD7p5l5EJk He will be greatly missed. https://t.co/Ll7cYiGtzs
-
-
Mashup Score: 8
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of COVID-19. Objective: To evaluate whether levels of plasma antigen can predict short-term clinical outcomes and identify clinical and viral factors associated with plasma antigen levels in hospitalized patients with…
Source: Annals of Internal MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Congratulations to @StanfordMedRes Associate Program Director @AJRogers_ICU on leading this impactful study across 114 centers -- just published in @AnnalsofIM! Plasma levels of SARS-CoV-2 antigen strongly correlate with #COVID outcomes. @StanfordDeptMed https://t.co/WA4YR0rFvi
-
-
Mashup Score: 4
AbstractBackgroundStatins taken for cardiovascular indications by patients with breast cancer and lymphoma during doxorubicin treatment may attenuate left ventricular ejection fraction (LVEF) decli…
Source: evidence.nejm.orgCategories: Cardiologists, Latest HeadlinesTweet-
Congrats to the investigators on this impressive & important study. Statins do not attenuate doxorubicin-induced LVEF drops in this careful evaluation. More thoughts to follow… #CardioOnc @NEJM https://t.co/4A4nKCOnAt
-
-
Mashup Score: 7JACC Achieves Highest Impact Factor to Date - 3 year(s) ago
Impressive growth in impact seen across the family of journals
Source: www.jacc.orgCategories: Cardiologists, Latest HeadlinesTweet-
Only the second Impact Factor #JACCCardioOnc - and already at 8.422! 🤯 Now a top-25 journal in all of #Cardiology! 🍾💥 A privilege to work with #BonnieKy and the entire Editorial team. @JACCJournals #CardioOnc https://t.co/53m2iaChCT
-
-
Mashup Score: 0
BACKGROUND The Medical Student Performance Evaluations (MSPE) is a cornerstone of residency applications. Little is known regarding adherence to Association of American Medical Colleges (AAMC) MSPE recommendations and longitudinal changes in MSPE content. OBJECTIVES Evaluate current MSPE quality and longitudinal changes in MSPE and grading practices. DESIGN Retrospective analysis. PARTICIPANTS…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet-
Obfuscation and grade inflation in #MedicalSchool MSPEs — shocking data from comprehensive analysis 2014-2020. Only 25% follow #AAMC recommendations! 77 unique keywords! Honors on 2-83% of clerkships depending on medical school! 😱😱😱 @StanfordDeptMed https://t.co/b3w6Qgv0Sc
-
-
Mashup Score: 2This Startup Raised $45 Million To Build A Community Health Worker Brigade For Medicaid - 3 year(s) ago
With Waymark, cofounders Rajaie Batniji and Sanjay Basu are banking that a combination of software and community-based care can help revolutionize the $600 billion Medicaid market and improve patients’ health.
Source: ForbesCategories: Cardiologists, Latest HeadlinesTweet-
Fantastic & innovative work and such a classic @StanfordMed story! Congrats to @StanfordMedRes alum @RBatniji and other members of the @StanfordDeptMed community. @vintweeta @HeartBobH https://t.co/PhtT8mVwGM
-
-
Mashup Score: 2Heart drug's trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data - MedCity News - 3 year(s) ago
BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved blockbuster Pfizer drug. BridgeBio attributed the trial failure to a surprisingly strong placebo response, and it will continue the study, hoping for better outcomes on additional goals.
Source: MedCity NewsCategories: Cardiologists, Latest HeadlinesTweet-
(1/9) A few thoughts re: today’s topline results for #acoramidis (AG10) @BridgeBioPharma for #ATTR #amyloidosis. The big takeaway — results are less surprising than first meet the eye, and should not be taken to mean the drug won’t work. https://t.co/DQATBkDiEi
-
-
Mashup Score: 12
A CardioNerds Case Report of young women presenting with Complete Heart Block In A Young Adult – Stanford University
Source: CardionerdsCategories: Cardiologists, Latest HeadlinesTweet-
Always such fun working with @CardioNerds! Great work by @pablosanchezcas @Maggienut @JamesETooley from @StanCVFellows on this case discussion! @StopSarcoidosis @StanfordDeptMed #sarcoid https://t.co/FCcjZMUBVC
-
-
Mashup Score: 6Mistaken Identity: Using Bone Scintigraphy to Diagnose Cardiac Amyloidosis in Patients With a Monoclonal Gammopathy - 3 year(s) ago
Central Illustration
Source: JACC: CardioOncologyCategories: Cardiologists, Latest HeadlinesTweet-
Congratulations to @StanfordMedRes PGY-2 @anguyen4194 for his outstanding manuscript in the #amyloidosis special issue of @JACCJournals #JACCCardioOncology! Beware the #PYP scan without ruling out a monoclonal gammopathy! @KMAlexanderMD @StanfordDeptMed https://t.co/CrDhB5QcM7 https://t.co/aOfD6FgdWX
-
Proud to present the November 2022 mini-focus issue on #amyloidosis in @JACCJournals #JACCCardioOncology. Follows up last year’s fantastic Amyloidosis special issue. Check it out! 🥳 https://t.co/kA3hHQMe1s